Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Effectiveness of Sustained Release TKI Hydrogel Combined with Bevacizumab in a VEGF Induced Retinal Leakage Model Through 12 Months

Rami F Elhayek; Tim Jarrett; Zachary Lattrell; Erica Kahn; Stephen Takach; Jamie Lynne Metzinger; Michael H Goldstein; Peter K Jarrett; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):245.

ARVO Annual Meeting Abstract July 2018

Efficacy & Tolerability of OTX-TKI, a Sustained Hydrogel Delivery System for a Tyrosine Kinase Inhibitor, in a VEGF Induced Retinal Leakage Model Through 12 Months

Peter K Jarrett; Rami F Elhayek; Tim Jarrett; Zachary Lattrell; Erica Kahn; Stephen Takach; Jamie Lynne Metzinger; Michael H Goldstein; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3465.

ARVO Annual Meeting Abstract June 2017

Tolerability of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in Dutch Belted Rabbits

Peter K Jarrett; Rami F Elhayek; Tim Jarrett; Zach Lattrell; Michael McGrath; Stephen Takach; Jonathan H. Talamo; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1956.

ARVO Annual Meeting Abstract June 2017

Pharmacokinetics of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in Dutch Belted Rabbits

Tim Jarrett; Rami F Elhayek; Zach Lattrell; Michael McGrath; Stephen Takach; Peter K Jarrett; Jonathan H. Talamo; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1984.

ARVO Annual Meeting Abstract June 2017

Efficacy of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in a VEGF Induced Retinal Leakage Model

Rami F Elhayek; Tim Jarrett; Zach Lattrell; Stephen Takach; Peter K Jarrett; Michael McGrath; Jonathan H Talamo; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1968.

ARVO Annual Meeting Abstract June 2017

Tolerability of a Shape Changing Intravitreal Hydrogel Depot

Arthur Driscoll; Charles D Blizzard; Jonathan H Talamo; Peter K Jarrett; Rami F Elhayek; Tim Jarrett; Zach Lattrell; Michael McGrath; Stephen Takach; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1980.

ARVO Annual Meeting Abstract September 2016

Tolerability of In Situ Forming Intravitreal Hydrogel Depots for Anti-VEGF Sustained Release in a Rabbit Model

Charles D Blizzard; Courtney Rosales; Timothy Jarrett; Rami F Elhayek; sarah guedez; Andrew Vanslette; Peter K Jarrett; Arthur Driscoll; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1120.

ARVO Annual Meeting Abstract September 2016

Sustained Delivery of Cyclosporine from an Intracanalicular Depot in a Canine Model

Daniel Lee Smoot; Rami F Elhayek; Zachary Lattrell; Mike McGrath; Timothy Jarrett; Courtney Rosales; Peter K Jarrett; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):423.

ARVO Annual Meeting Abstract June 2015

Tolerability of Intravitreal Hydrogel Depots for Anti-VEGF Sustained Release in a Rabbit Model

Peter K Jarrett; Rami F Elhayek; Sarah Guedez; Courtney Rosales; Timothy S. Jarrett; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1496.

ARVO Annual Meeting Abstract June 2015

Pharmacokinetics of Bevacizumab Sustained Release from Intravitreal Hydrogel Depots in a Rabbit Model Compared to a single Avastin Dose

Rami F Elhayek; Peter K Jarrett; Amar Sawhney; Arthur Driscoll; Timothy S. Jarrett; Courtney Rosales; Andrew Vanslette; Charles D Blizzard; sarah guedez

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1522.

Advertisement